Pharmaceutical giant Eli Lilly continues to announce major investments in its U.S. manufacturing footprint as it reshores operations and upgrades facilities. Its fourth and latest announcement will see $3.5 billion invested in Lehigh Valley, Pennsylvania to construct a state-of-the-art manufacturing facility for its weight-loss drug production. The project will bring 850 jobs to the region including engineers, scientists, operations personnel, and lab technicians.
The project, which is the largest investment by a life sciences company in the state to date, has received $100 million in support from the Pennsylvania Department of Community and Economic Development. Construction is slated to begin this year. The state is also providing up to $5 million to a local community college or technical school to offer workforce development services. The project was accelerated under Pennsylvania’s Permit Fast Track Program.
“To meet increasing demand, we’re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next-generation weight-loss medicines,” David Ricks, Eli Lilly Chair and CEO, said in a statement. “We’re creating high-quality jobs and collaborating across the region—with suppliers, educators, and workforce-development partners—to make critical medicines in the U.S.”
The manufacturing facility will feature advanced technologies including AI, integrated monitoring, and data analytics to optimize efficiency and reliability across operations. This is part of a greater push by the manufacturer to invest more than $50 billion to construct and refurbish its U.S. factories as part of its reshoring efforts and to remain competitive with other players in the space who have made similar investments in the U.S.
